We care for a healthy future Welcome to Curetis AG. We are a young, dynamic and creative molecular diagnostics company specializing in the development of simple and rapid solutions for diagnosing severe infectious diseases in hospitalized patients. Our solutions enable physicians to detect antibiotic resistances at an early stage and thus fight infections efficiently. Curetis AG is not a typical biotech start-up company. As a newcomer to the market, the company has drawn upon its experienced, multidisciplinary team to make significant progress over the last seven years. Dr. Katja Schwarzer, Clinical Trial Specialist Katja is responsible for implementing and supporting clinical trials in Germany and Europe and, in particular, for the FDA study in the USA. Guido Sarnowski, Manager Supply Chain Guido cultivates our partnerships in procurement and distribution logistics and ensures that our customers receive the correct quantity of products at the right time and in the right place. The wealth of med-tech expertise held by our development engineers and the scientific knowledge held by our microbiologists has enabled us to launch Unyvero a fully integrated, commercial molecular diagnostics platform for hospitals and large laboratories. Our goal is to continuously develop this platform for additional infectious diseases over the next few years and to continue to grow as a company at both of our sites in Holzgerlingen and Bodelshausen in Germany and we want to achieve this with you, whether this is as an employee or an investor. Oliver Schacht, PhD, CEO Oliver has many years of experience in biotech management and is responsible for the international growth of Curetis AG. He also ensures that we always have the right people on board, and that they are able to communicate with one another about important issues whenever necessary.
Andreas Boos, CTO Andreas is responsible for all aspects relating to the technical and scientific development of the Unyvero platform be it devices, software, new bio-assays in the cartridges or continuously improving our products. He is also responsible for ensuring that the company complies with the applicable standards and for organizing and overseeing approval procedures. a CONTINUOUS improvement About Us We are not a conventional R&D company we focus primarily on commercial product development. This involves listening to our customers very carefully and responding quickly and flexibly to current market needs and demands. We then develop intelligent and pragmatic solutions to meet these requirements. "Even though our company is growing all the time, we still have the same frame of mind and operate in the same way as we did when we first started." Our founders play an active role in the company and drive continuous improvements in all areas of the business, together with the 50 employees that the company now has at two locations in Germany and with an internationally oriented team of sales managers and application specialists. Johannes Bacher, COO Johannes is responsible for all operational activities in production, supply chain, finance and administrative areas. He has an overview of everything that Curetis requires in terms of personnel, materials, resources and operational coordination so that the products can be distributed and made available to customers. Curetis AG Founded: August 2007 Locations: Holzgerlingen (headquarters) Bodelshausen (cartridge production) Number of employees: approx. 50 (01/01/2014) Business area: Molecular diagnostic systems for hospitals and large laboratories The management team at Curetis has many years of experience in product development, clinical trials, approval procedures, business development, production and marketing. Additional Information and Facts > More than 100 Unyvero Systems have been built > More than 20,000 cartridges have been manufactured > More than two million injection molded plastics parts have been processed > More than 2,000 patient samples have been analyzed 4 5
2007 Company Formation A group of engineers, doctors and biologists from Philips founded Curetis AG. This group includes today's CTO Andreas Boos, COO Johannes Bacher, Director Bio-Assay Development Dr. Gerd Lüdke and Medical Director Dr. Anne Thews. 2008 Initial Seed Capital In addition to the capital increase provided by the founders and the management team, aeris CAPITAL AG, a family office based in Switzerland, invests EUR 1.4 million in Curetis AG. 2009 Series A Venture Capital Round overall, some EUR 20 million in capital is acquired from a syndicate made up of aeris Capital, LSP, BioMed Invest, KfW and a number of local family businesses, as well as the management team and the company's founders. The business plan and product pipeline are realigned. 2010 Unyvero Development Milestones The first prototypes of the Unyvero Systems are developed in collaboration with Zollner Elektronik AG. Together with Contexo, a pilot plant is set up for the production facility that will produce Unyvero Cartridges. 2011 The Series A financing round is extended and the production facility opens. Oliver Schacht joins the Curetis team as CEO. CD-Venture, Forbion Capital Partners and the Roche Venture Fund are added to the company's list of investors. Collaboration with Sanofi Pasteur begins. 2013 SERIES B financing round successfully closed. 2013/2014 Entering new international markets in the Middle East, Russia, Benelux, Southeastern Europe, Portugal and Spain. HBM Partners becomes the new lead investor. To date, a total of EUR 49.1 million in equity capital has been raised. The business develops internationally. FDA approval study starts in the USA. OUR INVESTORS' SUCCESS 2012 The Unyvero System with the First Cartridge for Pneumonia Is Launched in Germany, Austria and Switzerland The CE evaluation study successfully concludes, a multicenter clinical trial is started in Europe and collaboration with Heraeus Medical and Cempra Pharmaceuticals begins. 2014 The second cartridge: Unyvero i60 ITI is launched and the company aims to enter more new markets. Curetis AG Milestones Over the last seven years, Curetis has continuously grown and established itself in the market, making the company a real success story. It all started with the idea for Unyvero. The company then moved onto the development and approval process, before going on to penetrate international med-tech markets. The company has focused on delivering high quality right from the get-go. This approach, coupled with the company's strong pioneering spirit and the simple statement "We Care for Diagnostics" and due in no small part to our outstanding engineering prowess and molecular and microbiological expertise is what has won over our investors, customers and partners. There are two areas that offer Curetis potential for further growth: the establishment and development of international markets globally, and the expansion of the Unyvero System with a pipeline of new cartridges. By taking these opportunities, our goal is to develop even further and offer our investors attractive exit opportunities, e.g. an IPO. 6 7
simple and intelligent solutions Comprehensive Development Expertise and A Solution-Focused Approach An exceptional understanding of the market and a high level of customer focus are the most important factors in Curetis' success. The highly qualified, multi-functional team is made up of experienced developers from the industry and PhD-level microbiologists who optimally support the applications side towards our customers. We are not a conventional research company we focus primarily on commercial product development. This means that we do not focus on creating innovative solutions at all costs, but rather cultivate a distinctly pragmatic way of thinking and working. We first listen to our customers very carefully, and then combine established technology with new ideas. With this philosophy in mind, we aim to continuously develop the Unyvero platform as we move forward and address new markets with varying country-specific requirements. We therefore consider ourselves a long-term partner and associate of intensive-care specialists, microbiologists, laboratory personnel and hospital management teams. We all share the same goal: to fight severe infectious diseases and the spreading of these diseases faster and more efficiently. Dr. Karin Förster-Fromme, Clinical Application Specialist Karin is responsible for providing our customers, distributors and sales personnel with technical and scientific support, as well as creating marketing literature for our products. Wolfgang Maurer, Senior Engineer Wolfgang is responsible for project management with our production partner Zollner and other suppliers. He is also responsible for the collaborative project with Sanofi Pasteur, who are looking to use the Unyvero solution in a global phase IIb trial. 8
Uwe Wolf, Manufacturing Manager Uwe is responsible for the production of Unyvero Cartridges and consumables and ensures the smooth running of operational activities at the production facility in Bodelshausen. Unyvero The Unyvero platform developed by Curetis is a fast, comprehensive diagnostics system for severe infectious diseases in hospitalized patients. A range of cartridges enable illnesses such as pneumonia or even infected wounds and tissue infections to be diagnosed easily within only four to five hours, whether this is done in a hospital laboratory or directly at the "point of need" in the intensive care unit. quick, simple and highly multiplexed applications Unyvero L4 Lysator Unyvero C8 Cockpit Unyvero A50 Analyzer Unyvero Application Cartridges The Unyvero System is an innovative, molecular diagnostic multiplex test system that covers all steps, right from the sample to the test result. It is made up of the following: Unyvero L4 Lysator for the lysis of native patient samples; Unyvero A50 Analyzer to handle and read out the cartridge; Unyvero C8 Cockpit with intuitive user interaction and control. Device-specific software as well as two different disposable cartridges for pneumonia and wound and tissue infections complete the system. Unyvero P50 Pneumonia The Unyvero Pneumonia Application is used to detect acute infections in the lungs and respiratory tracts of hospitalized patients. In such cases, the time factor, in particular, determines the required isolation and the corresponding antibiotic treatments. Thanks to a comprehensive panel, this cartridge can detect 22 resistance markers and 17 pathogens and can be used for patients who have received previous treatment. The bottom line is that Unyero P50 Pneumonia achieves considerable cost savings by shortening hospital stays and lowering the costs of antibiotics. panel - 22 resistance markers - 17 pathogens Unyvero i60 ITI (Implant & Tissue Infection) The Unyvero ITI Application has eight application areas and can detect all major tissue and wound infections. It can be used following operations and transplants, as well as for burn wounds and diabetic feet. The cartridge comprises the entire sample spectrum and offers an extremely comprehensive panel with more than 20 resistance markers and more than 90 pathogens. The results enable infections to be managed more effectively and can be used and interpreted in a variety of ways, such as for acute care, surgical planning, treatment planning for burn wounds or for long-term therapy. panel - 23 resistance markers - 91 pathogens Additional Unyvero Cartridges for other infectious diseases are currently in development. 10 12 13
You care for the best and most efficient therapy a COMPETENT partner network a solid financial base SIMPLIFYING DIAGNOSTICS Unyvero quickly and reliably detects infections and antibiotic resistance and, in so doing, enables specific decisions regarding therapy to be made at an early stage and patients with multi-resistant germs to be put in isolation in good time. As a result, patients benefit from earlier and improved therapy and hospitals can realize considerable savings thanks to shorter hospital stays where case-based lump sums (DRG) are concerned. The risk of infection and the significant costs incurred as a result are minimized by isolating infected patients early on. Experienced board members with broad expertise The supervisory board at Curetis boasts outstanding expertise in areas including in-vitro diagnostics, life sciences and venture capital, and supports and assists Curetis with its activities along the entire value chain. A Top-Notch NETWORK OF INTERNATIONAL PARTNERS To supplement the core areas of expertise held by Curetis, the company has cultivated partnerships with well-established, globally successful companies such as Sanofi Pasteur, Heraeus Medical and Cempra. In addition, a prospective clinical trial of the Unyvero System and the Unyvero P50 Pneumonia Cartridge has been successfully completed in the European Union in collaboration with clinical partners. What's more, an observational study with a subsequent intervention arm is currently being performed by external clinical experts, taking place at three centers. INVESTORS AND FUNDING In total, Curetis AG has acquired EUR 49.1 million in equity capital from an international group of investors over the course of three financing rounds. The institutional investors include aeris CAPITAL, LSP Life Sciences Partners, BioMedPartners, CD-Venture, Forbion Capital Partners, the Roche Venture Fund, HBM Partners and the KfW banking group ERP start-up fund. Moreover, Curetis AG has received public funding in excess of EUR 1 million to date. This funding was part of the Central SME Innovation Programme ran by the German Federal Ministry for Economic Affairs and Energy. Unyvero functions according to the "Plug & Play" principle and can be operated quickly and easily at any time regardless of laboratory opening times by doctors, lab technicians and nursing staff without a great deal of prior experience in the laboratory. Sabrina Tietze, Purchasing Sabrina is responsible for purchasing all goods and services and ensures that customers all over the world receive their deliveries on time. 11 "Leading clinical experts working as external advisors and an outstanding network of scientists and representatives from the life sciences and medical engineering sectors further enable us to garner expert opinions from leading specialists." Dr. Helmut Hilbert, Head of Business Development Helmut is responsible for developing the business and expanding it on a global scale by identifying new distribution partners and working with pharmaceutical and diagnostics companies that use products from Curetis for their clinical trials, thereby helping to commercialize these products worldwide. Jutta Feiler, Executive Assistant Jutta is responsible for the company's general organization and ensures that everything runs smoothly for the executive committee and the supervisory board. As the "heart and soul" of Curetis, Jutta also organizes all company events and celebrations. 14 15
a strong team Tim Codanda, Software Developer Tim is responsible for software development and ensures that every user can use the Unyvero solution easily and intuitively. CAREER PROSPECTS AT CURETIS Our most important resources are our employees. the fringes of the Schönbuch, on the outskirts of Stuttgart, or As a young, dynamic, growing business in the diagnostics at our production facility in Bodelshausen in the middle of sector, our main focus is on cultivating a transparent and the "Medical Valley" on the fringes of the Swabian Alb. Both open working environment, adopting a flexible way of locations are ideal environments to live in and offer a high working and communicating with one another in an informal quality of life and a wide range of leisure opportunities to manner. Our work is characterized by mutual respect and young families in particular. a high level of tolerance. From the very start, our distinctive corporate culture has Marion Grieser, Lab Technician Marion is responsible for the R&D laboratory and ensures that the development projects run smoothly and that experiments are optimized accordingly. Learn more about Curetis and find job vacancies here We offer attractive jobs in a highly qualified, multi-functional been based on an employee-oriented set of values that team. Our staff are either based at our headquarters, which fosters a sense of responsibility and motivates employees. We look forward to receiving your application has excellent transport links and is located in Holzgerlingen on The company languages are German and English. please send it by email to hr@curetis.com 16 17
Curetis AG Max-Eyth-Str. 42 71088 Holzgerlingen Germany Tel.:+49 (0)7031/49195-10 email: contact@curetis.com www.curetis.com You?